Alzinova (STO:ALZ) First Quarter 2025 Results
Key Financial Results
- Revenue: kr6.09m (up 114% from 1Q 2024).
- Net loss: kr5.68m (loss widened by 14% from 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Alzinova Earnings Insights
Looking ahead, revenue is expected to decline by 35% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Sweden are expected to grow by 16%.
Performance of the Swedish Biotechs industry.
The company's shares are down 6.3% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Alzinova has 5 warning signs (and 2 which shouldn't be ignored) we think you should know about.
Valuation is complex, but we're here to simplify it.
Discover if Alzinova might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.